九強生物(300406.SZ):目前尚不具備研發和生產“鍀[99mTc]肼基煙酰胺聚乙二醇雙環RGD肽注射液”的能力
格隆匯6月9日丨九強生物(300406.SZ)在投資者互動平台表示,公司目前尚不具備研發和生產“鍀[99mTc]肼基煙酰胺聚乙二醇雙環RGD肽注射液”的能力,該產品涉及多肽合成、放射性標記及注射液製劑工藝等,需具備專門的生產資質和技術水平。公司目前聚焦體外診斷領域,已在伴隨診斷相關抗體及靶點開發方面積累了較強的技術基礎,未來願在相關領域尋求合作機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.